Share on StockTwits

PDL BioPharma (NASDAQ:PDLI) saw a significant increase in short interest in April. As of April 15th, there was short interest totalling 27,784,655 shares, an increase of 8.1% from the March 31st total of 25,703,011 shares, ARN reports. Currently, 18.7% of the shares of the company are sold short. Based on an average trading volume of 3,724,668 shares, the short-interest ratio is currently 7.5 days.

PDLI has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of PDL BioPharma in a research note on Tuesday, April 22nd. They now have a $8.75 price target on the stock.

PDL BioPharma (NASDAQ:PDLI) opened at 8.49 on Thursday. PDL BioPharma has a 1-year low of $7.38 and a 1-year high of $10.21. The stock has a 50-day moving average of $8.30 and a 200-day moving average of $8.51. The company has a market cap of $1.361 billion and a P/E ratio of 5.07.

PDL BioPharma (NASDAQ:PDLI) last issued its quarterly earnings data on Monday, March 3rd. The company reported $0.39 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by $0.04. The company had revenue of $110.10 million for the quarter, compared to the consensus estimate of $115.22 million. During the same quarter in the previous year, the company posted $0.34 earnings per share. The company’s revenue for the quarter was up 28.0% on a year-over-year basis. On average, analysts predict that PDL BioPharma will post $1.84 earnings per share for the current fiscal year.

PDL BioPharma, Inc (NASDAQ:PDLI) is a is a biotech company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.